Creative Biolabs Expands IND-Enabling Live Biotherapeutic Product Safety Assessment Capabilities

(MENAFN- GetNews) Creative Biolabs has expanded its integrated Live Biotherapeutic Product (LBP) Safety Assessment suite, tailored specifically for natural, isolated, and genetically modified LBP strains.

New York, USA - September 11, 2026 - As therapeutic developers advance pipelines across gastroenterology, immuno-oncology, and metabolic diseases, comprehensive LBP safety testing and biocontainment testing have become critical. Translating living microorganisms into approved biotherapeutics requires verifiable evidence that candidate strains do not propagate antibiotic resistance genes (ARGs) or escape targeted biocontainment protocols. Creative Biolabs' enhanced testing portfolio bridges the gap between bioinformatic prediction and wet-lab empirical validation.

LBP Genomic Safety and Antibiotic Resistance Gene Assessment

Short-read whole-genome sequencing often leaves structural gaps, collapsing repeat regions and obscuring whether resistance or virulence genes reside on the chromosome or extrachromosomal plasmids. Utilizing long-read sequencing platforms (PacBio and Oxford Nanopore Technologies) at typical >100x sequencing coverage, Creative Biolabs delivers long-read genome closure and mobile genetic element risk profiling. This approach resolves circular chromosomes, characterizes plasmid replicons, and maps the genomic context of transposons, integrons, and prophages. By precisely locating ARGs within stable chromosomal regions versus mobilizable elements, developers can confidently make critical go/no-go candidate decisions early in the pipeline.

Horizontal Gene Transfer Risk Assessment for Live Biotherapeutic Products

Aligning with FDA and EMA guidelines for live biotherapeutic products, regulatory assessment commonly requires developers to characterize the potential for therapeutic microorganisms to transmit genetic material to the native human microbiome or opportunistic pathogens. Beyond computational mobility scoring, Creative Biolabs provides dedicated horizontal gene transfer (HGT) risk assessment. The workflow integrates in vitro conjugation assays and co-culture challenge models across liquid broth, agar, and physiologically relevant microaerobic or anaerobic environments. Deploying validated panel screening, selective plating, and molecular confirmation assays (such as PCR and plasmid profiling), researchers can accurately quantify transfer frequencies down to sensitive detection limits (typically 10^8 to 10^9). This empirical data helps validate whether bioinformatic predictions translate into functional, real-world transfer risks.

Biocontainment and Escape Frequency Testing for Engineered LBPs

For synthetic biology platforms deploying recombinant or genetically engineered strains, evaluating environmental containment is paramount. Creative Biolabs supports engineered pipelines with comprehensive biocontainment and kill-switch robustness validation. The testing protocol interrogates synthetic gene circuits across four criteria:

Basal Leakage Analysis: Evaluating strain viability to ensure switches remain silent during bioprocessing.

Triggered Elimination: Quantifying lethality kinetics across chemical, thermal, nutrient, pH, or oxygen-sensing triggers.

Escape-Frequency Assays: Calculating viable escape rates against defined limits (e.g.,

Genetic Stability: Monitoring circuit integrity across extended serial passaging (e.g., 50+ generations), formulation, and post-recovery stresses.

This comprehensive testing helps prove that engineered kill switches remain stable and effective throughout manufacturing, storage, and environmental exposure.

Key Deliverables

Closed genome and plasmid maps

ARG and virulence annotation reports

Mobile genetic element risk assessment

HGT transfer-frequency data

Escape-frequency and detection-limit reports

Genetic stability passaging data

Integrated safety summaries tailored for regulatory submissions

By combining closed-genome mapping, functional transfer testing, and synthetic circuit validation-typically within a 4-to-8 week turnaround time-Creative Biolabs provides biotherapeutic developers with an end-to-end preclinical safety framework to support regulatory submissions and development decision-making. Developers evaluating genomic safety, HGT potential, or biocontainment strategies for an LBP candidate can consult Creative Biolabs to design a stage-appropriate safety assessment program. For more information, visit .

About Creative Biolabs

Creative Biolabs is a specialized provider of biotechnology services and products, focusing on antibody engineering, therapeutic discovery, and advanced in vitro pharmacological profiling to support the global pharmaceutical research community.

MENAFN11092026003238003268ID1111651599